Silvia Cometta

Dr. Silvia Cometta

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2024 in Biomaterials
Verified
Journal Article
Open access
SCSilvia Cometta
Silvia Cometta
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
LCLiraz Chai
Liraz Chai
Biofilm research has grown exponentially over the last decades, arguably due to their contribution to hospital acquired infections when they form on foreign body surfaces such as catheters and implants. Yet, translation of the knowledge acquired in the laboratory to the clinic has been slow and/or often it is not attempted by research teams to walk the talk of what is defined as 'bench to bedside'. We therefore reviewed the biofilm literature to better understand this gap. Our search revealed substantial development with respect to adapting surfaces and media used in models to mimic the clinical settings, however many of the in vitro models were too simplistic, often discounting the composition and properties of the host microenvironment and overlooking the biofilm-implant-host interactions. Failure to capture the physiological growth conditions of biofilms in vivo results in major differences between lab-grown- and clinically-relevant biofilms, particularly with respect to phenotypic profiles, virulence, and antimicrobial resistance, and they essentially impede bench-to-bedside translatability. In this review, we describe the complexity of the biological processes at the biofilm-implant-host interfaces, discuss the prerequisite for the development and characterization of biofilm models that better mimic the clinical scenario, and propose an interdisciplinary outlook of how to bioengineer biofilms in vitro by converging tissue engineering concepts and tools.

16 November 2021 in Polymers
Verified
Journal Article
Open access
PDF file
MVMargaux Vigata
Margaux Vigata
COCathal D. O'Connell
Cathal D. O'Connell
SCSilvia Cometta
Silvia Cometta
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
Christoph MeinertChristoph Meinert
Christoph Meinert
Nathalie BockNathalie Bock
Nathalie Bock
The tuneability of hydrogels renders them promising candidates for local drug delivery to prevent and treat local surgical site infection (SSI) while avoiding the systemic side-effects of intravenous antibiotic injections. Here, we present a newly developed gelatin methacryloyl (GelMA)-based hydrogel drug delivery system (GelMA-DDS) to locally deliver the broad-spectrum antibiotic cefazolin for SSI prophylaxis and treatment. Antibiotic doses from 3 µg to 90 µg were loaded in photocrosslinked GelMA hydrogel discs with 5 to 15% w/v polymer concentration and drug encapsulation efficiencies, mechanical properties, crosslinking and release kinetics, as well as bacterial growth inhibition were assessed. Our results demonstrate that all GelMA groups supported excellent drug encapsulation efficiencies of up to 99%. Mechanical properties of the GelMA-DDS were highly tuneable and unaffected by the loading of small to medium doses of cefazolin. The diffusive and the proteolytic in vitro drug delivery of all investigated cefazolin doses was characterized by a burst release, and the delivered cefazolin amount was directly proportional to the encapsulated dose. Accelerated enzymatic degradation of the GelMA-DDS followed zero-order kinetics and was dependent on both the cefazolin dose and GelMA concentration (3–13 h). Finally, we demonstrate that cefazolin delivered from GelMA induced a dose-dependent antibacterial efficacy against S. aureus, in both a broth and a diffusive assay. The cefazolin-loaded GelMA-DDS presented here provides a highly tuneable and easy-to-use local delivery system for the prophylaxis and treatment of SSI.

17 October 2022 in ACS Nano
Verified
Journal Article
Open access
SCSilvia Cometta
Silvia Cometta
RJRobert T. Jones
Robert T. Jones
AJAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
BDBogdan Donose
Bogdan Donose
MYMuhammad Yasir
Muhammad Yasir
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
Biomaterial-associated infections are one of the major causes of implant failure. These infections result from persistent bacteria that have adhered to the biomaterial surface before, during, or after surgery and have formed a biofilm on the implant's surface. It is estimated that 4 to 10% of implant surfaces are contaminated with bacteria; however, the infection rate can be as high as 30% in intensive care units in developed countries and as high as 45% in developing countries. To date, there is no clinical solution to prevent implant infection without relying on the use of high doses of antibiotics supplied systemically and/or removal of the infected device. In this study, melimine, a chimeric cationic peptide that has been tested in Phase I and II human clinical trials, was immobilized onto the surface of 3D-printed medical-grade polycaprolactone (mPCL) scaffolds via covalent binding and adsorption. X-ray photoelectron spectroscopy (XPS) and time-of-flight secondary ion mass spectrometry (ToF-SIMS) spectra of melimine-treated surfaces confirmed immobilization of the peptide, as well as its homogeneous distribution throughout the scaffold surface. Amino acid analysis showed that melimine covalent and noncovalent immobilization resulted in a peptide density of ∼156 and ∼533 ng/cm2, respectively. Furthermore, we demonstrated that the immobilization of melimine on mPCL scaffolds by 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide hydrochloride (EDC) coupling and noncovalent interactions resulted in a reduction of Staphylococcus aureus colonization by 78.7% and 76.0%, respectively, in comparison with the nonmodified control specimens. Particularly, the modified surfaces maintained their antibacterial properties for 3 days, which resulted in the inhibition of biofilm formation in vitro. This system offers a biomaterial strategy to effectively prevent biofilm-related infections on implant surfaces without relying on the use of prophylactic antibiotic treatment.

1 December 2024 in Bioactive Materials
Verified
Journal Article
Open access
SCSilvia Cometta
Silvia Cometta
BDBogdan Donose
Bogdan Donose
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
ARAkhilandeshwari Ravichandran
Akhilandeshwari Ravichandran
YXYanan Xu
Yanan Xu
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
Biofilm-related biomaterial infections are notoriously challenging to treat and can lead to chronic infection and persisting inflammation. To date, a large body of research can be reviewed for coatings which potentially prevent bacterial infection while promoting implant integration. Yet only a very small number has been translated from bench to bedside. This study provides an in-depth analysis of the stability, antibacterial mechanism, and biocompatibility of medical grade polycaprolactone (mPCL), coated with human serum albumin (HSA), the most abundant protein in blood plasma, and tannic acid (TA), a natural polyphenol with antibacterial properties. Molecular docking studies demonstrated that HSA and TA interact mainly through hydrogen-bonding, ionic and hydrophobic interactions, leading to smooth and regular assemblies. In vitro bacteria adhesion testing showed that coated scaffolds maintained their antimicrobial properties over 3 days by significantly reducing S. aureus colonization and biofilm formation. Notably, amplitude modulation-frequency modulation (AMFM) based viscoelasticity mapping and transmission electron microscopy (TEM) data suggested that HSA/TA-coatings cause morphological and mechanical changes on the outer cell membrane of S. aureus leading to membrane disruption and cell death while proving non-toxic to human primary cells. These results support this antibiotic-free approach as an effective and biocompatible strategy to prevent biofilm-related biomaterial infections.

11 March 2026 in Agronomy
Verified
Journal Article
Open access
PDF file
Rut Mara Arteaga OjedaRut Mara Arteaga Ojeda
Rut Mara Arteaga Ojeda
CLClaudia Patricia Larralde-Corona
Claudia Patricia Larralde-Corona
SCSilvia Cometta
Silvia Cometta
JNJose Alberto Narvaez-Zapata
Jose Alberto Narvaez-Zapata
Biological control agents (BCAs) have emerged as a key strategy to mitigate maize diseases while reducing dependence on synthetic agrochemicals, which pose risks to human health, ecosystems, and microbial diversity. This review synthesizes advances from 63 research articles published between 2020 and 2025, selected through a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach to capture studies with in vitro, greenhouse, or field validation. The analysis highlights major fungal and bacterial threats to maize production and evaluates BCAs, including Bacillus, Trichoderma, Streptomyces, and entomopathogenic or endophytic microorganisms, tested across multiple experimental levels. Results show that many agents demonstrate strong antagonism under controlled conditions, promoting plant growth, reducing pathogen incidence, and lowering mycotoxin contamination. Field trials, however, reveal inconsistent performance due to environmental variability, formulation instability, and incomplete understanding of strain-specific mechanisms. Emerging approaches such as microbial consortia, metabolite-based biocontrol, biochar–microbe combinations, and evaluations under dual-stress conditions offer promising avenues to improve reliability and expand applicability. Overall, the review underscores that although microbial biocontrol holds substantial potential for sustainable maize protection, progress toward scalable implementation requires integrating omics-based characterization, optimized formulations, genotype-specific evaluations, and multi-season field trials to bridge the gap between laboratory efficacy and field performance.

16 June 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
SCSilvia Cometta
Silvia Cometta
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
In this comprehensive study, we delve into the intricate binding properties of tannic acid (TA) and examine their dual role in the realm of biomaterial development. While TA’s properties can enhance the functionality and performance of biomaterials, they also raise concerns regarding potential biases in in vitro biocompatibility assessments. We focus on the relevance and constraints of several widely employed cell viability assays, namely the DNA-based PicoGreen assay, the PrestoBlue assay, and the Live/Dead staining technique utilizing fluorescein diacetate (FDA) and propidium iodide (PI). We investigate how these assays perform when applied to TA-coated scaffolds and cell sheets. Through a detailed presentation of our experimental findings, we juxtapose them through a critical review of the existing literature, allowing us to identify and elucidate the limitations these assays face when assessing TA-based biomaterials. In doing so, we aim not only to enhance the understanding of these potential assay biases but also to provide actionable recommendations for accurately evaluating the biocompatibility of TA-modified substances. This dual approach, combining empirical research with literature analysis, offers vital insights for the research community, ensuring that the assessment of TA-coated biomaterials is scientifically sound and reproducible.